The ADA presentations (June 7) may provide near-term sentiment lift but are unlikely to be material without new efficacy data. The primary catalyst is the Q4 2026 DA-1726 Phase 1 Part 3 data readout. Monitor for any pre-ADA abstract releases or data leaks.
Price Chart
Executive Summary
MetaVia Inc. announced that three late-breaking abstracts on its cardiometabolic assets DA-1726 (GLP-1/glucagon dual agonist for obesity) and vanoglipel (GPR119 agonist for MASH/T2D) were accepted for poster presentations at the ADA 2026 Scientific Sessions (June 5-8). The filing is a routine pipeline update with no new clinical data disclosed; the key catalyst is the Phase 1 Part 3 titration study data for DA-1726 expected in Q4 2026.
Key Facts
- Three late-breaking abstracts accepted for ADA 2026 (June 5-8, New Orleans).
- DA-1726 Phase 1 Part 3 titration study data expected in Q4 2026.
- Two preclinical posters on vanoglipel combination therapies with resmetirom (MASH) and metformin (T2D).
- No new clinical data or financial figures disclosed in this filing.
Financial Impact
No financial data reported; pre-revenue clinical-stage biotech with $6M market cap.
Risk Factors
- DA-1726 is still in Phase 1; clinical failure or tolerability issues could wipe out value.
- Micro-cap ($6M) with high cash burn risk — no revenue and likely need for near-term financing.
- Competitive obesity market dominated by Novo Nordisk and Eli Lilly.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-063059 |
| Document: mtva-20260518xex99d1.htm | 0001104659-26-063059 |
| Document: 0001104659-26-063059-index-headers.html | 0001104659-26-063059 |
| Document: 0001104659-26-063059-index.html | 0001104659-26-063059 |
| Document: 0001104659-26-063059.txt | 0001104659-26-063059 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 3 | $1.36 | awaiting T+20 | — | $1.17 (−13.97%) |
Oct 13, 2026 14d ago | 8-K | $1.43 | awaiting T+20 | — | $1.17 (−18.18%) |
Sep 9, 2026 6w ago | 8-K | $1.74 $1.46 | ▼ −16.09% | ▼ −18.04% | $1.17 (−32.76%) |
Jul 9, 2026 15w ago | 8-K | $1.73 $1.45 | ▼ −16.18% | ▼ −18.43% | $1.17 (−32.37%) |
Jul 2, 2026 16w ago | 424B5 | $1.48 $1.44 | ▲ +2.70% | ▲ +2.29% | $1.17 (+20.95%) |
Jun 8, 2026 20w ago | 8-K | $1.89 $1.58 | ▼ −16.40% | ▼ −17.85% | $1.17 (−38.10%) |
Jun 8, 2026 20w ago | 8-K | $2.22 $1.51 | ▼ −31.98% | ▼ −33.61% | $1.17 (−47.30%) |
May 27, 2026 21w ago | 8-K | $3.34 $1.53 | ▼ −54.19% | ▼ −52.29% | $1.17 (−64.97%) |
May 18, 2026 23w ago | 8-K | $1.11 $1.65 | ▲ +48.65% | ▲ +47.07% | $1.17 (+5.41%) |
May 14, 2026 23w ago | 8-K | $1.11 $1.71 | ▲ +54.05% | ▲ +51.94% | $1.17 (+5.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers